{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:58:38Z","timestamp":1782737918043,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific and Technological Development Research Project Foundation of Shaanxi Province","award":["No.2020SF-069"],"award-info":[{"award-number":["No.2020SF-069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MicroRNA-141(miR-141) has been reported to play vital roles in the regulation of carcinogenesis and cancer progression. However, the biological function of miR-141 in GBC has received less attention. The aim of this study was to estimate the potential value of the expression level of miR-141 as a diagnostic and prognostic blood-based biomarker in gallbladder cancer (GBC) patients. Meanwhile, to explore its biological role in GBC cells. RT-PCR was employed to confirm the expression of miR-141 in ten paired tissue samples (10 GBC tissues and 10 adjacent normal gallbladder tissues), GBC cell lines and peripheral blood specimens from 98 GBC patients and 60 healthy controls. MTT assay was used to evaluate the GBC cells proliferation and flow cytometry was used to detect the cell apoptosis. Receiver operating characteristic curve analysis and the area under the curve (AUC) were used to evaluate the value of miR-141 plasma levels for GBC diagnosis. Finally, clinicopathological and survival data of all GBC patients were collected and analyzed. Here, we confirmed that the expression of miR-141 were upregulated in primary gallbladder cancer cells and tissues compared with human gallbladder epithelial cells and adjacent normal tissues (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). Meanwhile, we found that downregulated expression of miR-141 by miR-141 inhibitor could induce apoptosis and inhibit proliferation of GBC cells. Additionally, elevated plasma miR-141 expression was also detected in the peripheral blood of GBC patients compared with healthy controls (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). The AUC value of miR-141 for GBC diagnosis was 0.894 (95% CI 0.843\u20130.945), which was more valuable than those including carcinoembryonic antigen (CEA) (0.713, 95% CI 0.633\u20130.793), carbohydrate antigen 125 (CA125) (0.837, 95% CI 0.776\u20130.899) and carbohydrate antigen 19\u20139 (CA19-9) (0.869, 95% CI 0.813\u20130.924). The high expression level of miR-141 in plasma was significantly associated with tumor invasion (<jats:italic>P<\/jats:italic>\u2009=\u20090.008), lymph node metastasis (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and advanced pathologic tumor\/node\/metastasis (pTNM) stage (<jats:italic>P<\/jats:italic>\u2009=\u20090.009). More importantly, high plasma miR-141 expression was an independent prognostic factor for predicting poorer long-term survival in GBC patients. Elevated expression of circulating miR-141 in peripheral blood might be a potential novel biomarker for diagnosis and prognosis of GBC patients. Downregulated expression of miR-141 could inhibit proliferation and induce apoptosis of GBC cells, that provide a potential therapeutic target for GBC.<\/jats:p>","DOI":"10.1038\/s41598-022-13430-8","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T09:03:26Z","timestamp":1655370206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Circulating miR-141 as a potential biomarker for diagnosis, prognosis and therapeutic targets in gallbladder cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Ganghua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fandi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"13430_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"13430_CR2","doi-asserted-by":"publisher","first-page":"12211","DOI":"10.3748\/wjg.v21.i43.12211","volume":"21","author":"TO Goetze","year":"2015","unstructured":"Goetze, T. O. Gallbladder carcinoma: Prognostic factors and therapeutic options. World J. Gastroenterol. 21, 12211\u201312217. https:\/\/doi.org\/10.3748\/wjg.v21.i43.12211 (2015).","journal-title":"World J. Gastroenterol."},{"key":"13430_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/sla.0000000000002385","volume":"266","author":"GG Kasumova","year":"2017","unstructured":"Kasumova, G. G. et al. Surgical management of gallbladder cancer: Simple versus extended cholecystectomy and the role of adjuvant therapy. Ann. Surg. 266, 625\u2013631. https:\/\/doi.org\/10.1097\/sla.0000000000002385 (2017).","journal-title":"Ann. Surg."},{"key":"13430_CR4","doi-asserted-by":"publisher","first-page":"26404","DOI":"10.18632\/oncotarget.15476","volume":"8","author":"DS Bai","year":"2017","unstructured":"Bai, D. S., Chen, P., Qian, J. J., Jin, S. J. & Jiang, G. Q. Effect of marital status on the survival of patients with gallbladder cancer treated with surgical resection: A population-based study. Oncotarget 8, 26404\u201326413. https:\/\/doi.org\/10.18632\/oncotarget.15476 (2017).","journal-title":"Oncotarget"},{"key":"13430_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166361","volume":"11","author":"C Chen","year":"2016","unstructured":"Chen, C. et al. Long-term outcomes and prognostic factors in advanced gallbladder cancer: Focus on the advanced T stage. PLoS ONE 11, e0166361. https:\/\/doi.org\/10.1371\/journal.pone.0166361 (2016).","journal-title":"PLoS ONE"},{"key":"13430_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3892\/mco.2016.905","volume":"5","author":"G Yang","year":"2016","unstructured":"Yang, G., Zhang, L., Li, R. & Wang, L. The role of microRNAs in gallbladder cancer. Mol. Clin. Oncol. 5, 7\u201313. https:\/\/doi.org\/10.3892\/mco.2016.905 (2016).","journal-title":"Mol. Clin. Oncol."},{"key":"13430_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/emmm.201100209","volume":"4","author":"MV Iorio","year":"2012","unstructured":"Iorio, M. V. & Croce, C. M. MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143\u2013159. https:\/\/doi.org\/10.1002\/emmm.201100209 (2012).","journal-title":"EMBO Mol. Med."},{"key":"13430_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","volume":"12","author":"MY Shah","year":"2016","unstructured":"Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G. & Calin, G. A. microRNA therapeutics in cancer: An emerging concept. EBioMedicine 12, 34\u201342. https:\/\/doi.org\/10.1016\/j.ebiom.2016.09.017 (2016).","journal-title":"EBioMedicine"},{"key":"13430_CR9","doi-asserted-by":"publisher","first-page":"8538","DOI":"10.1002\/jcp.26850","volume":"233","author":"L Jamali","year":"2018","unstructured":"Jamali, L. et al. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J. Cell Physiol. 233, 8538\u20138550. https:\/\/doi.org\/10.1002\/jcp.26850 (2018).","journal-title":"J. Cell Physiol."},{"key":"13430_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lungcan.2018.06.027","volume":"123","author":"S Lu","year":"2018","unstructured":"Lu, S. et al. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer 123, 44\u201351. https:\/\/doi.org\/10.1016\/j.lungcan.2018.06.027 (2018).","journal-title":"Lung Cancer"},{"key":"13430_CR11","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3892\/ol.2018.8995","volume":"16","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Circulating plasma microRNAs in the detection of esophageal squamous cell carcinoma. Oncol. Lett. 16, 3303\u20133318. https:\/\/doi.org\/10.3892\/ol.2018.8995 (2018).","journal-title":"Oncol. Lett."},{"key":"13430_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.gene.2018.06.037","volume":"673","author":"X Zhou","year":"2018","unstructured":"Zhou, X. et al. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene 673, 181\u2013193. https:\/\/doi.org\/10.1016\/j.gene.2018.06.037 (2018).","journal-title":"Gene"},{"key":"13430_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000438641","volume":"38","author":"Y Gao","year":"2016","unstructured":"Gao, Y. et al. The roles of microRNA-141 in human cancers: From diagnosis to treatment. Cell Physiol. Biochem. 38, 427\u2013448. https:\/\/doi.org\/10.1159\/000438641 (2016).","journal-title":"Cell Physiol. Biochem."},{"key":"13430_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-018-9654-1","author":"H Dong","year":"2018","unstructured":"Dong, H. et al. The regulatory network of miR-141 in the inhibition of angiogenesis. Angiogenesis https:\/\/doi.org\/10.1007\/s10456-018-9654-1 (2018).","journal-title":"Angiogenesis"},{"key":"13430_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.5114\/aoms.2017.68757","volume":"14","author":"S Li","year":"2018","unstructured":"Li, S., Zhu, J., Li, J. & Li, B. MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1. Arch. Med. Sci. 14, 588\u2013596. https:\/\/doi.org\/10.5114\/aoms.2017.68757 (2018).","journal-title":"Arch. Med. Sci."},{"key":"13430_CR16","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.21873\/anticanres.11828","volume":"37","author":"ZH Long","year":"2017","unstructured":"Long, Z. H. et al. miR-141 inhibits proliferation and migration of colorectal cancer SW480 cells. Anticancer Res. 37, 4345\u20134352. https:\/\/doi.org\/10.21873\/anticanres.11828 (2017).","journal-title":"Anticancer Res."},{"key":"13430_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41598-018-36854-7","volume":"9","author":"E Richardsen","year":"2019","unstructured":"Richardsen, E. et al. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Sci. Rep. 9, 386. https:\/\/doi.org\/10.1038\/s41598-018-36854-7 (2019).","journal-title":"Sci. Rep."},{"key":"13430_CR18","doi-asserted-by":"publisher","DOI":"10.2174\/1574892814666181231142136","author":"JH Zhang","year":"2018","unstructured":"Zhang, J. H. & Xia, H. B. Lentiviral-mediated overexpression of MicroRNA-141 promotes cell proliferation and inhibits apoptosis in human esophageal squamous cell carcinoma. Recent Pat. Anticancer Drug Discov. https:\/\/doi.org\/10.2174\/1574892814666181231142136 (2018).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"13430_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.5009\/gnl15460","volume":"10","author":"J Kim","year":"2016","unstructured":"Kim, J., Ryu, J. K., Lee, S. H. & Kim, Y. T. MicroRNA 141 expression is a potential prognostic marker of biliary tract cancers. Gut Liver 10, 836\u2013841. https:\/\/doi.org\/10.5009\/gnl15460 (2016).","journal-title":"Gut Liver"},{"key":"13430_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/ott.s95565","volume":"9","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco. Targets. Ther. 9, 139\u2013148. https:\/\/doi.org\/10.2147\/ott.s95565 (2016).","journal-title":"Onco. Targets. Ther."},{"key":"13430_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3892\/ol.2020.11959","volume":"20","author":"H Wu","year":"2020","unstructured":"Wu, H. & Yan, H. Expression and diagnostic value of miR-34c and miR-141 in serum of patients with colon cancer. Oncol. Lett. 20, 98. https:\/\/doi.org\/10.3892\/ol.2020.11959 (2020).","journal-title":"Oncol. Lett."},{"key":"13430_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/hpb.12444","volume":"17","author":"TA Aloia","year":"2015","unstructured":"Aloia, T. A. et al. Gallbladder cancer: Expert consensus statement. HPB (Oxford) 17, 681\u2013690. https:\/\/doi.org\/10.1111\/hpb.12444 (2015).","journal-title":"HPB (Oxford)"},{"key":"13430_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mrrev.2018.08.003","volume":"778","author":"R Mehrotra","year":"2018","unstructured":"Mehrotra, R. et al. Genetic landscape of gallbladder cancer: Global overview. Mutat. Res. 778, 61\u201371. https:\/\/doi.org\/10.1016\/j.mrrev.2018.08.003 (2018).","journal-title":"Mutat. Res."},{"key":"13430_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000443842","volume":"33","author":"Y Nasu","year":"2016","unstructured":"Nasu, Y., Hirano, S., Tsuchikawa, T. & Shichinohe, T. Aggressive surgery for locally advanced gallbladder cancer with obstructive jaundice: Result of a prospective study. Dig. Surg. 33, 213\u2013219. https:\/\/doi.org\/10.1159\/000443842 (2016).","journal-title":"Dig. Surg."},{"key":"13430_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12029-017-0036-5","volume":"49","author":"SK Shukla","year":"2018","unstructured":"Shukla, S. K., Singh, G., Shahi, K. S. & Pant, P. Staging, treatment, and future approaches of gallbladder carcinoma. J. Gastrointest. Cancer 49, 9\u201315. https:\/\/doi.org\/10.1007\/s12029-017-0036-5 (2018).","journal-title":"J. Gastrointest. Cancer"},{"key":"13430_CR26","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3892\/ol.2018.9189","volume":"16","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. Prognostic validation of the updated 8th edition Tumor-Node-Metastasis classification by the Union for International Cancer Control: Survival analyses of 307 patients with surgically treated gallbladder carcinoma. Oncol. Lett. 16, 4427\u20134433. https:\/\/doi.org\/10.3892\/ol.2018.9189 (2018).","journal-title":"Oncol. Lett."},{"key":"13430_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","volume":"20","author":"J Hayes","year":"2014","unstructured":"Hayes, J., Peruzzi, P. P. & Lawler, S. MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol. Med. 20, 460\u2013469. https:\/\/doi.org\/10.1016\/j.molmed.2014.06.005 (2014).","journal-title":"Trends Mol. Med."},{"key":"13430_CR28","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.3748\/wjg.v24.i30.3313","volume":"24","author":"A Link","year":"2018","unstructured":"Link, A. & Kupcinskas, J. MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. World J. Gastroenterol. 24, 3313\u20133329. https:\/\/doi.org\/10.3748\/wjg.v24.i30.3313 (2018).","journal-title":"World J. Gastroenterol."},{"key":"13430_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/15384047.2014.1002327","volume":"16","author":"D Yuan","year":"2015","unstructured":"Yuan, D., Li, K., Zhu, K., Yan, R. & Dang, C. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol. Ther. 16, 268\u2013275. https:\/\/doi.org\/10.1080\/15384047.2014.1002327 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"13430_CR30","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.1158\/0008-5472.can-08-1942","volume":"68","author":"CP Bracken","year":"2008","unstructured":"Bracken, C. P. et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68, 7846\u20137854. https:\/\/doi.org\/10.1158\/0008-5472.can-08-1942 (2008).","journal-title":"Cancer Res."},{"key":"13430_CR31","doi-asserted-by":"publisher","first-page":"966","DOI":"10.18632\/oncotarget.26629","volume":"10","author":"C Papadaki","year":"2019","unstructured":"Papadaki, C. et al. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. Oncotarget 10, 966\u2013981. https:\/\/doi.org\/10.18632\/oncotarget.26629 (2019).","journal-title":"Oncotarget"},{"key":"13430_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000490726","volume":"95","author":"S Santasusagna","year":"2018","unstructured":"Santasusagna, S. et al. Prognostic impact of miR-200 family members in plasma and exosomes from tumor-draining versus peripheral veins of colon cancer patients. Oncology 95, 309\u2013318. https:\/\/doi.org\/10.1159\/000490726 (2018).","journal-title":"Oncology"},{"key":"13430_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13277-014-2656-8","volume":"36","author":"XL Wang","year":"2015","unstructured":"Wang, X. L. et al. Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumour Biol. 36, 877\u2013883. https:\/\/doi.org\/10.1007\/s13277-014-2656-8 (2015).","journal-title":"Tumour Biol."},{"key":"13430_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12943-017-0582-2","volume":"16","author":"CS Mak","year":"2017","unstructured":"Mak, C. S. et al. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12\/Sp1\/survivin axis. Mol. Cancer 16, 11. https:\/\/doi.org\/10.1186\/s12943-017-0582-2 (2017).","journal-title":"Mol. Cancer"},{"key":"13430_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28416","author":"G Han","year":"2019","unstructured":"Han, G., Qiu, N., Luo, K., Liang, H. & Li, H. Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4. J. Cell Biochem. https:\/\/doi.org\/10.1002\/jcb.28416 (2019).","journal-title":"J. Cell Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13430-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:48:26Z","timestamp":1669355306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13430-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13430"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13430-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10072"}}